GlaxoSmithKline Stock Price, News & Analysis (NYSE:GSK)

$36.84 +0.27 (+0.74 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$36.84
Today's Range$36.61 - $36.90
52-Week Range$34.52 - $44.53
Volume2.78 million shs
Average Volume4.81 million shs
Market Capitalization$89.74 billion
P/E Ratio24.72
Dividend Yield7.34%
Beta0.98

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:GSK
CUSIPN/A
Phone+44-20-80475000

Debt

Debt-to-Equity Ratio4.09%
Current Ratio0.60%
Quick Ratio0.39%

Price-To-Earnings

Trailing P/E Ratio24.7248322147651
Forward P/E Ratio12.75
P/E Growth2.26

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.35
Cash Flow$4.42 per share
Price / Cash8.33
Book Value$1.81 per share
Price / Book20.35

Profitability

Trailing EPS$1.49
Net Income$1.97 billion
Net Margins4.97%
Return on Equity130.63%
Return on Assets10.28%

Miscellaneous

Employees99,827
Outstanding Shares2,479,100,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Wednesday, February 7th. Shareholders of record on Friday, February 23rd will be paid a dividend of $0.633 per share on Thursday, April 12th. This represents a $2.53 annualized dividend and a yield of 6.87%. The ex-dividend date is Thursday, February 22nd. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.50. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, February, 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating the Zacks' consensus estimate of $0.69 by $0.03. The pharmaceutical company earned $10.14 billion during the quarter, compared to the consensus estimate of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. View GlaxoSmithKline's Earnings History.

When will GlaxoSmithKline make its next earnings announcement?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

Where is GlaxoSmithKline's stock going? Where will GlaxoSmithKline's stock price be in 2018?

13 equities research analysts have issued 12 month target prices for GlaxoSmithKline's shares. Their predictions range from $37.00 to $40.00. On average, they expect GlaxoSmithKline's stock price to reach $39.00 in the next year. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer, Executive Director (Age 47)
  • Simon Dingemans, Chief Financial Officer, Executive Director (Age 53)
  • Patrick Vallance, President - R&D, Executive Director (Age 56)
  • Roger Connor, President - Global Manufacturing & Supply
  • Luc Debruyne, President - Global Vaccines
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare (Age 50)
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E. Troy, Senior Vice President, General Counsel

Who owns GlaxoSmithKline stock?

GlaxoSmithKline's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.52%), Renaissance Technologies LLC (0.39%), Bank of New York Mellon Corp (0.23%), Two Sigma Advisers LP (0.20%), Raymond James & Associates (0.16%) and NWQ Investment Management Company LLC (0.11%). View Institutional Ownership Trends for GlaxoSmithKline.

Who sold GlaxoSmithKline stock? Who is selling GlaxoSmithKline stock?

GlaxoSmithKline's stock was sold by a variety of institutional investors in the last quarter, including Miller Howard Investments Inc. NY, Schafer Cullen Capital Management Inc., Confluence Investment Management LLC, Equity Investment Corp, BlackRock Inc., Raymond James & Associates, Chartwell Investment Partners LLC and Macquarie Group Ltd.. View Insider Buying and Selling for GlaxoSmithKline.

Who bought GlaxoSmithKline stock? Who is buying GlaxoSmithKline stock?

GlaxoSmithKline's stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Millennium Management LLC, Two Sigma Investments LP, Armistice Capital LLC, Arrowstreet Capital Limited Partnership, Clark Estates Inc. NY, OLD Republic International Corp and Sei Investments Co.. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy GlaxoSmithKline stock?

Shares of GlaxoSmithKline can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GlaxoSmithKline stock can currently be purchased for approximately $36.84.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $89.74 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $1.49 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The pharmaceutical company can be reached via phone at +44-20-80475000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  692 (Vote Underperform)
Total Votes:  1,053
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.232.202.202.47
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.00$38.33$43.50$43.50
Price Target Upside: 4.64% upside2.22% upside20.43% upside6.49% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018CowenReiterated RatingHold$40.00LowView Rating Details
2/9/2018Kepler Capital MarketsUpgradeReduce -> HoldLowView Rating Details
2/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralHighView Rating Details
1/16/2018BarclaysUpgradeEqual Weight -> OverweightLowView Rating Details
11/30/2017ArgusLower Price TargetBuy$40.00LowView Rating Details
11/6/2017InvestecDowngradeBuy -> HoldN/AView Rating Details
10/26/2017Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
9/8/2017Morgan StanleyDowngradeEqual Weight -> UnderweightLowView Rating Details
7/27/2017CitigroupReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs GroupReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018        
2/7/2018n/a$0.69$0.72$9.89 billion$10.14 billionViewN/AView Earnings Details
10/25/2017Q3 2017$0.84$0.85$10.22 billion$10.26 billionViewN/AView Earnings Details
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
7/27/2016Q2 2016$0.55$0.70$8.35 billion$9.22 billionViewN/AView Earnings Details
4/27/2016Q1 2016$0.60$0.57$8.59 billion$8.92 billionViewN/AView Earnings Details
2/3/2016Q4 2015$0.52$0.55$9.36 billion$9.62 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2013Q1 2013$0.77$0.82$10.13 billion$9.87 billionViewN/AView Earnings Details
2/6/2013Q4 2012$0.96$1.04ViewN/AView Earnings Details
10/31/2012Q3 2012$0.89$0.85ViewN/AView Earnings Details
7/25/2012Q2 2012$0.84$0.82ViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
10/26/2011Q3 2011$0.90$0.89ViewN/AView Earnings Details
7/26/2011Q2 2011$0.77$0.81ViewN/AView Earnings Details
4/27/2011Q1 2011$1.00$1.02ViewN/AView Earnings Details
2/3/2011Q4 2010$0.88$0.91ViewN/AView Earnings Details
7/21/2010Q2 2010$0.88$0.10ViewN/AView Earnings Details
4/28/2010Q1 2010$0.86$0.93ViewN/AView Earnings Details
2/7/2010Q4 2009$1.12$1.14ViewN/AView Earnings Details
11/2/2009Q3 2009$0.96$0.93ViewN/AView Earnings Details
7/22/2009Q2 2009$0.86$1.02ViewN/AView Earnings Details
2/5/2009Q4 2008$0.80$0.81ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

2018 EPS Consensus Estimate: $3.05
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.69$0.69$0.69
Q2 20181$0.82$0.82$0.82
Q3 20181$0.86$0.86$0.86
Q4 20181$0.68$0.68$0.68
(Earnings estimates data provided by Zacks Investment Research)

Dividends

GlaxoSmithKline (NYSE:GSK) Dividend Information

Next Dividend:4/12/2018
Annual Dividend:$2.53
Dividend Yield:6.87%
Dividend Growth:-8.90% (3 Year Average)
Payout Ratio:169.80% (Trailing 12 Months of Earnings)
87.54% (Based on This Year's Estimates)
84.90% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2018Quarterly$0.630.0173472184160044%2/22/20182/23/20184/12/2018
10/26/2017quarterly$0.505.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.494.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.484.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.575.76%2/22/20172/24/20174/13/2017
10/26/2016$0.4611/2/201611/4/20161/12/2017
7/27/2016$0.498/10/20168/12/201610/13/2016
4/28/2016$0.555/11/20165/13/20167/14/2016
10/28/2015$0.5811/10/201511/13/20151/14/2016
5/7/2015quarterly$0.585.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.706.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.615.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.655.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.755.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.624.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.554.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.554.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.070.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.17%
Insider Trades by Quarter for GlaxoSmithKline (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
Arrowstreet Capital Limited Partnership Has $25.46 Million Position in GlaxoSmithKline plc (GSK)Arrowstreet Capital Limited Partnership Has $25.46 Million Position in GlaxoSmithKline plc (GSK)
www.americanbankingnews.com - February 24 at 12:56 PM
GlaxoSmithKline plc (GSK) Position Lowered by Raymond James Financial Services Advisors Inc.GlaxoSmithKline plc (GSK) Position Lowered by Raymond James Financial Services Advisors Inc.
www.americanbankingnews.com - February 24 at 7:54 AM
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View SolidEmergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
finance.yahoo.com - February 23 at 5:04 PM
Endo, Glaxo to Settle Suits Over Testosterone-Replacement DrugsEndo, Glaxo to Settle Suits Over Testosterone-Replacement Drugs
finance.yahoo.com - February 23 at 5:04 PM
The Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'ReillyThe Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'Reilly
finance.yahoo.com - February 23 at 9:00 AM
How GlaxoSmithKline plc (LON:GSK) Delivered A Better ROE Than Its IndustryHow GlaxoSmithKline plc (LON:GSK) Delivered A Better ROE Than Its Industry
finance.yahoo.com - February 22 at 5:08 PM
How Eli Lilly’s Cardiovascular Portfolio Performed in 4Q17How Eli Lilly’s Cardiovascular Portfolio Performed in 4Q17
finance.yahoo.com - February 22 at 5:08 PM
After back-to-back busts, MedImmune wins key federal nod for its flu vaccineAfter back-to-back busts, MedImmune wins key federal nod for its flu vaccine
finance.yahoo.com - February 21 at 5:09 PM
GlaxoSmithKline (GSK) Downgraded by Zacks Investment ResearchGlaxoSmithKline (GSK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:34 PM
Analysts’ Recommendations for GlaxoSmithKline after 4Q17 EarningsAnalysts’ Recommendations for GlaxoSmithKline after 4Q17 Earnings
finance.yahoo.com - February 21 at 9:26 AM
Promacta and Jakavi May Boost Novartis’s Oncology Segment RevenuesPromacta and Jakavi May Boost Novartis’s Oncology Segment Revenues
finance.yahoo.com - February 20 at 4:58 PM
GlaxoSmithKline’s Consumer Healthcare Business in 4Q17GlaxoSmithKline’s Consumer Healthcare Business in 4Q17
finance.yahoo.com - February 20 at 4:58 PM
GlaxoSmithKline plc (GSK) Raises Dividend to $0.63 Per ShareGlaxoSmithKline plc (GSK) Raises Dividend to $0.63 Per Share
www.americanbankingnews.com - February 17 at 9:30 AM
GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-YearGlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year
finance.yahoo.com - February 16 at 5:04 PM
GlaxoSmithKline (GSK) Stock Rating Reaffirmed by CowenGlaxoSmithKline (GSK) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - February 15 at 4:30 PM
Dodge & Cox Comments on GlaxoSmithKlineDodge & Cox Comments on GlaxoSmithKline
finance.yahoo.com - February 14 at 3:29 PM
GlaxoSmithKline (GSK), Innoviva (INVA) Submit IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta - StreetInsider.comGlaxoSmithKline (GSK), Innoviva (INVA) Submit IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta - StreetInsider.com
www.streetinsider.com - February 14 at 6:55 AM
CDC Still Recommends Sanofi (NYSE:SNY), GlaxoSmithKline ... - BenzingaCDC Still Recommends Sanofi (NYSE:SNY), GlaxoSmithKline ... - Benzinga
www.benzinga.com - February 13 at 6:56 AM
GlaxoSmithKline plc -- Moodys: M&A greatest downside risk to European pharma companies credit quality in 2018GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018
finance.yahoo.com - February 12 at 6:55 AM
GlaxoSmithKline (GSK) Downgraded by TheStreet to CGlaxoSmithKline (GSK) Downgraded by TheStreet to C
www.americanbankingnews.com - February 10 at 2:28 PM
Why I’d buy and hold dividend stocks GlaxoSmithKline plc & Taylor Wimpey plcWhy I’d buy and hold dividend stocks GlaxoSmithKline plc & Taylor Wimpey plc
www.fool.co.uk - February 10 at 6:58 AM
GlaxoSmithKline (GSK) Upgraded by Kepler Capital Markets to "Hold"GlaxoSmithKline (GSK) Upgraded by Kepler Capital Markets to "Hold"
www.americanbankingnews.com - February 9 at 7:16 PM
Why Sanofi Has Received a Negative Outlook from Fitch RatingsWhy Sanofi Has Received a Negative Outlook from Fitch Ratings
finance.yahoo.com - February 9 at 3:34 PM
Glaxos Key Drug Gains Time as FDA Denies Novartis Generic ... - BloombergGlaxo's Key Drug Gains Time as FDA Denies Novartis Generic ... - Bloomberg
www.bloomberg.com - February 9 at 6:55 AM
Jacob Rees-Moggs Dreamland Is a Nightmare for Britains BossesJacob Rees-Mogg's Dreamland Is a Nightmare for Britain's Bosses
finance.yahoo.com - February 9 at 6:55 AM
GlaxoSmithKline Sees Unusually High Options Volume (GSK)GlaxoSmithKline Sees Unusually High Options Volume (GSK)
www.americanbankingnews.com - February 9 at 1:10 AM
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4 - NasdaqGlaxo (GSK) Earnings and Revenues Surpass Estimates in Q4 - Nasdaq
www.nasdaq.com - February 8 at 3:26 PM
Interesting GSK Put And Call Options For March 29th - NasdaqInteresting GSK Put And Call Options For March 29th - Nasdaq
www.nasdaq.com - February 8 at 3:26 PM
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4
finance.yahoo.com - February 8 at 3:26 PM
GlaxoSmithKline (GSK) Announces  Earnings Results, Beats Estimates By $0.03 EPSGlaxoSmithKline (GSK) Announces Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - February 8 at 11:16 AM
Glaxo (GSK) Stock Down Despite Q4 Earnings and Sales Beat - NasdaqGlaxo (GSK) Stock Down Despite Q4 Earnings and Sales Beat - Nasdaq
www.nasdaq.com - February 8 at 6:46 AM
GSK Expects Lower US Tax Rate Will Boost Profits - Wall Street Journal (blog)GSK Expects Lower US Tax Rate Will Boost Profits - Wall Street Journal (blog)
blogs.wsj.com - February 8 at 6:46 AM
Glaxos Key Drug Gains Time as FDA Denies Novartis GenericGlaxo's Key Drug Gains Time as FDA Denies Novartis Generic
finance.yahoo.com - February 8 at 6:46 AM
Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayedDrugmaker GSK wins fresh Advair reprieve as Novartis copy delayed
finance.yahoo.com - February 8 at 6:46 AM
Form 6-K GLAXOSMITHKLINE PLC For: Feb 07 - StreetInsider.comForm 6-K GLAXOSMITHKLINE PLC For: Feb 07 - StreetInsider.com
www.streetinsider.com - February 7 at 6:52 AM
What to watch in GlaxoSmithKline earningsWhat to watch in GlaxoSmithKline earnings
www.marketwatch.com - February 6 at 6:43 AM
The Chase for a Permanent Flu VaccineThe Chase for a Permanent Flu Vaccine
finance.yahoo.com - February 6 at 6:43 AM
GSK Is Focused on Innovative Assets in Oncology Research PipelineGSK Is Focused on Innovative Assets in Oncology Research Pipeline
finance.yahoo.com - February 5 at 3:25 PM
GlaxoSmithKline Is Global Leader in Consumer Healthcare BusinessGlaxoSmithKline Is Global Leader in Consumer Healthcare Business
finance.yahoo.com - February 5 at 3:25 PM
GlaxoSmithKline (GSK) Receives "Neutral" Rating from JPMorgan Chase & Co.GlaxoSmithKline (GSK) Receives "Neutral" Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - February 5 at 11:06 AM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Aerie Pharma, AstraZeneca, China Pharma, and GlaxoSmithKlineQuotidian Technical Highlights on Selected Drug Makers Stocks -- Aerie Pharma, AstraZeneca, China Pharma, and GlaxoSmithKline
www.bizjournals.com - February 5 at 6:50 AM
Glaxo, Reckitt Are Said to Be Only Suitors for Pfizers DivisionGlaxo, Reckitt Are Said to Be Only Suitors for Pfizer's Division
finance.yahoo.com - February 5 at 6:50 AM
Glaxo, Reckitt Submit Only Bids for Pfizers Consumer UnitGlaxo, Reckitt Submit Only Bids for Pfizer's Consumer Unit
finance.yahoo.com - February 3 at 3:29 PM
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season? - NasdaqIs a Beat in the Cards for Glaxo (GSK) This Earnings Season? - Nasdaq
www.nasdaq.com - February 3 at 6:49 AM
AstraZeneca: Analyst Ratings and RecommendationsAstraZeneca: Analyst Ratings and Recommendations
finance.yahoo.com - February 2 at 3:28 PM
How Sanofi Can Benefit from Ablynx AcquisitionHow Sanofi Can Benefit from Ablynx Acquisition
finance.yahoo.com - February 2 at 6:45 AM
How Does GlaxoSmithKline plc (LON:GSK) Fare As A Dividend Stock?How Does GlaxoSmithKline plc (LON:GSK) Fare As A Dividend Stock?
finance.yahoo.com - February 1 at 7:07 AM
Merck’s 4Q17 Estimates: Pharmaceutical SegmentMerck’s 4Q17 Estimates: Pharmaceutical Segment
finance.yahoo.com - January 31 at 3:26 PM
Nucala May Be a Game-Changing Product in Respiratory SegmentNucala May Be a Game-Changing Product in Respiratory Segment
finance.yahoo.com - January 31 at 6:57 AM
Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKlineTrelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline
finance.yahoo.com - January 31 at 6:57 AM

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlaxoSmithKline (NYSE GSK) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.